T richomonas vaginalis is one of the most common sexually transmitted infections (STIs) in the world. The World Health Organization estimated that in 2012, there were 143 million new cases of T. vaginalis, more than the incidence of Neisseria gonorrhoeae, Chlamydia trachomatis, or syphilis infections. 1 The high rates of T. vaginalis infection are particularly troubling in the context of adverse reproductive health and pregnancy outcomes. Women infected with T. vaginalis can experience a range of symptoms, including itching, vaginal discharge, and dysuria, as well as more significant complications such as pelvic inflammatory disease and fallopian tube pathology. 2, 3 T. vaginalis infection is also associated with an increased risk of acquiring HIV, 4 as well as increased vaginal shedding of HIV. 3 A woman infected with T. vaginalis during pregnancy is more likely to experience preterm delivery, premature rupture of membranes, and delivery of low-birth-weight infants. [5] [6] [7] In addition, T. vaginalis infection during pregnancy has been associated with an increased risk of vertical transmission of HIV. 8 T. vaginalis is a curable STI; thus, prompt detection and treatment are appropriate interventions to mitigate infectionassociated complications. Such interventions are particularly important in high-risk populations such as pregnant women and immunocompromised individuals. Estimates of the proportion of asymptomatic T. vaginalis infections are as high as 80%, 5 and the US Centers for Disease Control and Prevention (CDC) recommends screening for T. vaginalis among HIV-infected women, especially HIV-infected pregnant women. 9 Three classes of detection methods of increasing sensitivity commonly used to screen for T. vaginalis are wet-mount microscopy, culture, and nucleic acid amplification tests (NAATs).
Despite recommendations to routinely screen HIV-infected pregnant women for T. vaginalis, most settings still practice syndromic screening for detection of STIs. 10 The exquisite sensitivity of NAATs makes them great screening tools, but it also raises 2 important questions: (1) Which polymerase chain reaction (PCR)-positive cases are clinically significant (i.e., would not have been cleared if left untreated)? and (2) At what time point does a test-of-cure (ToC) test accurately detect a persistent infection rather than remnant nucleic acid from an infection that will soon be cleared? The goal of this study was to measure the effectiveness of NAAT screening for T. vaginalis and to attempt to understand the clinical significance of PCR positivity. To that end, we took advantage of the opportunity to compare culture and PCR for the detection of T. vaginalis as part of an ongoing study of STI detection among HIV-infected pregnant women.
MATERIALS AND METHODS

Study Participants
Participants were recruited from 2 clinics in the Soshanguve Township, Tshwane, South Africa, from June 2016 to May 2017.
All participants were HIV-infected pregnant women, older than 18 years, less than 34 weeks' gestation, and presenting for their first antenatal clinic visit for their current pregnancy. Women were assessed for eligibility, consented, and enrolled. Enrolled participants completed a baseline questionnaire, received basic antenatal care (ANC) clinical services from the study nurse per South African national guidelines, 10 and were asked to provide a self-collected vaginal swab for STI testing. The specimens used for this study were collected from a subset of women from a large cohort study assessing the acceptability, feasibility, and impact on birth outcomes of point-of-care PCR diagnosis and treatment of C. trachomatis, N. gonorrhoeae, and T. vaginalis.
Ethics
The study protocol was approved by the institutional review boards (IRBs) of the University of Pretoria (IRB Approval No. 401/2015) and the University of California, Los Angeles (IRB Approval No. 15-001351). All participants provided informed written consent.
PCR Testing
The GeneXpert (Cepheid, Sunnyvale, CA) diagnostic platform and Xpert TV test cartridges were used to screen for T. vaginalis.
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The Xpert TV test cartridge includes 3 internal controls: a sample processing control that detects the presence of PCR reaction inhibitors, a sample adequacy control that confirms the presence of human genes in the specimen, and a probe check control that verifies the integrity of the probe and reagent preparation. The Xpert TV Assay's limit of detection is reported by the manufacturer as 5 cells/mL. 12 The cycle threshold (Ct) values of positive PCR runs were recorded. The Ct value represents the number of PCR cycles before a reaction becomes positive, and is inversely related to the initial amount of nucleic acid being amplified; therefore, lower Ct values in an Xpert TV Assay indicate more T. vaginalis nucleic acid in a sample. Cycle threshold values for a positive GeneXpert Assay finding typically range between 15 and 40. 13 The Xpert TV Assay stops running after 40 cycles; therefore, no amplification by 40 cycles is interpreted as negative. HIV-infected pregnant women who tested positive for T. vaginalis were provided with a regimen of 400 mg of metronidazole, twice a day, for 7 days, in accordance with recommendations for similar regimens from the South African 10 and US CDC treatment guidelines. 9 AToC visit was scheduled for 3 weeks after treatment was initiated. Women who tested positive for T. vaginalis were provided 2 options for partner treatment: a referral for treatment at the clinic or a pill packet containing one 2-g dose of metronidazole.
T. vaginalis Culture
Women with positive Xpert TV test results were asked to provide an additional vaginal swab for culture using a FLOQSwab Dry Swab (Copan Diagnostics, Brescia, Italy). This sample was requested during the same visit as the Xpert TV testing, right after the test results were available. T. vaginalis culture was performed by inoculating the InPouch TV with the vaginal swab (Biomed, San Jose, CA) per the manufacturer's instructions. 14 The InPouch TV limit of detection has been reported to be 4 organisms per milliliters 15 and 0.2 organisms per reaction. 16 Inoculated InPouch cultures were incubated at clinic sites at 18°C to 37°C and were transported to the University of Pretoria within 36 hours of inoculation.
Upon arrival at the University of Pretoria, cultures were incubated at 37°C and observed by wet-mount microscopy daily for motile trichomonads. An InPouch was declared culture positive if motile trichomonads were observed within the first 7 days of incubation; if no motile trichomonads were observed in this time frame, the InPouch was declared culture negative.
Data Management and Statistics
Study data were collected and managed using REDCap electronic data capture tools hosted at the Foundation for Professional Development (Pretoria, South Africa). 17 GeneXpert Ct values for PCR-positive/culture-positive and PCR-positive/ culture-negative samples were compared to assess the parasite burden detected by PCR in the 2 groups. Cycle threshold values were tested for normality using the Shapiro-Wilk test, and data that were not normally distributed are reported here using median and interquartile range (IQR). The nonparametric Mann-Whitney U test was used to compare Ct values between groups. A receiver operating characteristic curve was calculated to determine the diagnostic characteristics of the Ct value in relation to culture positivity. The area under the curve was calculated to determine the accuracy of the Ct value as a diagnostic test, and the Youden Index was calculated to determine the optimal Ct threshold to predict culture positivity. A χ 2 test was performed to determine if there was a relationship between symptoms and culture positivity. All statistical tests were 2-tailed at a significance level (α) of 0.05. Calculations were performed using IBM SPSS Statistics for Windows (Version 24.0; IBM Corp., Armonk, NY). In contrast, all culture-negative cases had a Ct value greater than 30, except for 1 case (Ct = 19.1). The area under the receiver operating characteristic curve was 0.95 (P < 0.001); a Ct value less than 30 correctly predicted culture positivity with a sensitivity of 97% and a specificity of 96% (Youden Index, 0.93).
RESULTS
T. vaginalis Screening at Baseline
Fourteen cultures were not obtained from women who tested positive for T. vaginalis via PCR at baseline. Of those missing cultures, 6 were due to the fact that the PCR testing portion of the study was implemented before the availability of cultures at clinic sites, and 8 were not collected because of patient refusal. In addition, 1 culture was inconclusive (negative but was not read according to InPouch TV protocol) and so was excluded from the analyses. The demographic characteristics of these participants were not significantly different from the participants from whom cultures were collected (data not shown).
T. vaginalis Positivity and Symptoms at Baseline
Among the 34 women with self-reported symptoms and/or clinically observed signs of an STI, the median Ct value was 24.9 (IQR, 21.3-30.1), whereas the median Ct of the 37 with no signs and/or symptoms was 29.1 (IQR, 22.3-37.3). The difference in median Ct value between the 2 groups was 4.3 (P > 0.05).
Women with symptoms and/or signs of an STI were culture positive in 19 cases and culture negative in 10 cases. Those without symptoms or signs were also culture positive in 19 cases and culture negative in 10 cases. A χ 2 analysis revealed no significant difference in the number of positive cultures between those with symptoms and/or signs and those without (χ 2 = 0, P > 0.05). Five women were excluded from the symptom analysis because they did not respond to one or more questions on our survey of symptoms. Of those women, 2 were missing cultures (patient refusal); the other 3 had negative cultures. (n = 5) was 37.5 (IQR, 34.3-37.8). Four of the 5 PCR-positive/ culture-negative cases had a Ct value greater than 30. Three cultures were not obtained from women who tested positive for T. vaginalis via PCR at ToC visits because of patient refusal.
T. vaginalis Testing at ToC
Of the 13 PCR-positive women at ToC visits, 11 of them provided a response when asked about sexual activity between baseline and the ToC visit. Six (55%) reported having sexual intercourse at least once between the baseline and ToC visits; of these 6, 1 was culture positive, 3 were culture negative, and 2 were missing cultures. Among the 5 women who reported abstaining, 2 were culture negative, 2 were culture positive, and 1 was missing a culture.
DISCUSSION
We observed a high prevalence of T. vaginalis (20%) in a population of HIV-infected pregnant women seeking ANC at public health centers in South Africa. The prevalence in our cohort was similar to the prevalence found in other cohorts of South African women (20%) 18 and HIV-infected pregnant women in the Democratic Republic of Congo (18%) 19 and Nigeria (19%) 20 ; however, it was slightly less than those in other cohorts of HIVinfected women (30%) 21 and non-HIV infected pregnant women (41%) 22 in South Africa. The range of Ct values we observed in PCR-positive cases (18.3-39.9) was similar to that observed in another recent study of T. vaginalis prevalence in South African women (17.0-37.9). 18 We found that approximately half of the T. vaginalis infections were symptomatic, consistent with current estimates suggesting high proportions of asymptomatic T. vaginalis infection. 5, 18 Given the current policy of syndromic management of STIs in South Africa and most of the world, only symptomatic women would be treated for T. vaginalis during ANC. 10, 23 The CDC recommendation to screen HIV-infected pregnant women for T. vaginalis indicates a need to determine the most effective screening method. The current criterion standard in many settings for T. vaginalis diagnosis is culture. Our work shows that culture only detects T. vaginalis in roughly half of cases detected by PCR. Those findings suggest that culture may miss many cases of T. vaginalis, possibly due to low organism burden at the time of testing. Peterman and colleagues 24 found evidence suggesting that T. vaginalis may be undetectable by culture at one visit but then become detectable at a subsequent visit, without any intervening sexual contact.
Although PCR detects many cases that culture misses, the clinical significance of those PCR-positive/culture-negative cases is less certain. The high sensitivity of PCR means that some women who would clear an infection without any intervention may still test positive because of remnant protozoal nucleic acid in injured or phagocytosed cells. 25 Treating such cases means exposing women, and in our population fetuses as well, to unnecessary antibiotics. In addition, overuse of antibiotics increases the risk of developing resistant organisms.
Currently, there is no way to predict which PCR-positive cases will turn into clinically significant infections requiring antibiotic treatment and which will clear without intervention. We observed significantly lower Ct values in the PCR-positive/culture-positive cases, consistent with another study that compared T. vaginalis detection with the InPouch to a laboratory-based PCR method. 16 Our finding of a Ct threshold of less than 30 predicting culture positivity with a sensitivity of 97% and a specificity of 96% could be used to study which PCR-positive cases require treatment. If T. vaginalis infections with a Ct value greater than 30 are found to be clinically insignificant, use of this threshold would allow clinicians to obtain the benefits of increased speed, specificity, and ease of use provided by point-of-care PCR platforms, without worrying about the risk of overtreating.
The value of such a clinical study would be 2-fold. First, there is not strong evidence that culture positivity is a good proxy for clinical significance. In fact, we found no association between culture positivity and symptoms. Second, given the serious potential complications of a T. vaginalis infection, particularly in pregnant women, a strong argument could be made for treating any infection that is detected, that is, at least until more information is known about which PCR-positive cases truly require treatment. Another potential avenue for predicting clinically significant infections could lie in the use of viability PCR to differentiate DNA of cells with intact membranes from free-floating DNA. 26 The high sensitivity of PCR tests can also complicate ToC visits by detecting remnant nucleic acids from nonviable organisms after treatment. Williams and colleagues 27 found that 5 (10%) of 52 women testing positive for T. vaginalis by PCR were still positive at 3 weeks after treatment, but all 5 later tested negative at 5 weeks after treatment, without any additional treatment during the intervening period. The temporal relationship between the clearance of pathogen nucleic acid and PCR positivity remains to be elucidated with T. vaginalis testing, which may be one reason why the CDC has no recommendation regarding ToC after treatment of T. vaginalis. The guidelines do advise, however, that NAAT "can be conducted as soon as 2 weeks after treatment." 9 In a study investigating how long T. vaginalis nucleic acid remains detectable after metronidazole treatment, Martin and colleagues found that T. vaginalis RNA was no longer detectable by 3 weeks after treatment in a group of 34 women. Importantly, all of those women reported abstinence during this period and were InPouch culture positive at baseline and culture negative at subsequent visits. 28 In contrast to these results, we detected T. vaginalis DNA in 5 of 10 women who were culture negative at 3 weeks after treatment, and 2 of these women reported abstaining from intercourse during those 3 weeks. Although our sample size was small, the low rate of culture positivity at ToC may suggest that remnant T. vaginalis DNA persists at least as long as 3 weeks after treatment.
Cycle threshold values also proved informative in our ToC analyses, with the 5 positive cultures having a significantly smaller median Ct value. In addition, the Ct threshold of less than 30 predicted culture positivity with a sensitivity of 100% and a specificity of 80%.
Our study was conducted in a specific population of women who were both infected with HIV and pregnant. Although both of these altered physiological states can cause changes in the vaginal flora, we do not expect that these states would significantly alter PCR or culture results when screening for T. vaginalis. One might expect an increased susceptibility to T. vaginalis infection in HIV-infected women 18 ; however, as noted previously, we found prevalence rates in line with other studies in different populations. One limitation of this study is that we did not perform wet-mount microscopy or collect cultures from women who tested PCR negative for T. vaginalis. Although it is theoretically possible that some infections were missed, the generally accepted higher sensitivity of NAATs compared with both wet mount and culture suggests that this is unlikely. 3 Another limitation is that we only collected samples at the 3-week ToC. Multiple consecutive samples in women who did and did not receive treatment could shed more light on the question of clinical significance in PCRpositive/culture-negative cases.
In summary, we found high rates of T. vaginalis infection (symptomatic and asymptomatic) among HIV-infected pregnant women in Soshanguve Township, South Africa. We have shown that culture detects T. vaginalis organisms in only a portion of PCR-positive cases and demonstrated the potential utility of Ct values in the interpretation of PCR results. We highlight a 
